Long Road Investment Counsel LLC continued to hold its position in AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,994 shares of the company’s stock at the end of the 2nd quarter. Long Road Investment Counsel LLC’s holdings in AbbVie were worth $942,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ABBV. Acropolis Investment Management LLC bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $106,000. Hudock Capital Group LLC increased its position in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the last quarter. BDO Wealth Advisors LLC bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $115,000. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of AbbVie during the 1st quarter valued at approximately $108,000. Finally, Tradewinds Capital Management LLC increased its position in shares of AbbVie by 87.2% during the 1st quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock valued at $148,000 after purchasing an additional 1,057 shares during the last quarter. 69.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of AbbVie Inc. (NYSE ABBV) opened at $96.32 on Monday. AbbVie Inc. has a 1-year low of $58.80 and a 1-year high of $98.52. The firm has a market capitalization of $153,768.13, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 1.36 and a beta of 1.52. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The business had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same period in the prior year, the business earned $1.21 EPS. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. sell-side analysts predict that AbbVie Inc. will post 5.55 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.95%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. AbbVie’s dividend payout ratio is currently 62.29%.

Several research firms have recently weighed in on ABBV. UBS reissued a “neutral” rating on shares of AbbVie in a research report on Friday, October 13th. Jefferies Group boosted their price objective on AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a report on Monday, October 16th. Cowen restated a “hold” rating and set a $95.00 price objective (up previously from $70.00) on shares of AbbVie in a report on Monday, September 11th. Evercore ISI assumed coverage on AbbVie in a report on Wednesday, August 16th. They set an “outperform” rating and a $95.00 price objective for the company. Finally, BMO Capital Markets restated a “hold” rating and set a $84.00 price objective on shares of AbbVie in a report on Tuesday, November 21st. Seven equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $96.72.

In related news, VP Robert A. Michael sold 6,699 shares of the company’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the completion of the sale, the vice president now directly owns 10,007 shares in the company, valued at approximately $880,616. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the sale, the senior vice president now owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders sold a total of 277,125 shares of company stock valued at $25,891,756 over the last quarter. Company insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Long Road Investment Counsel LLC Maintains Holdings in AbbVie Inc. (ABBV)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/04/long-road-investment-counsel-llc-maintains-holdings-in-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.